Veracyte earnings were $88.0M for the trailing 12 months ending Mar 31, 2026, with 158.1% growth year over year. The latest VCYT earnings report on Mar 31, 2026 announced Q1 2026 earnings of $28.7M, down 30.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VCYT reported annual earnings of $66.4M, with 174.9% growth.
VCYT past earnings growth
How has VCYT's earnings growth performed historically?
On VCYT's earnings call on Invalid Date, Veracyte (NASDAQ: VCYT) reported Q1 2026 earnings per share (EPS) of $0.36, up 300% year over year. Total VCYT earnings for the quarter were $28.71 million. In the same quarter last year, Veracyte's earnings per share (EPS) was $0.09.
As of the last Veracyte earnings report, Veracyte is currently profitable. Veracyte's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $88.01 million, a 166.31% increase year over year.
What was VCYT's earnings growth in the past year?
As of Veracyte's earnings date in Invalid Date, Veracyte's earnings has grown 158.14% year over year. This is 110.9 percentage points higher than the US Biotechnology industry earnings growth rate of 47.24%. VCYT earnings in the past year totalled $88.01 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.